Home > Journals > Otorinolaringologia > Past Issues > Otorinolaringologia 2004 June;54(2) > Otorinolaringologia 2004 June;54(2):131-40





A Journal on Otorhinolaryngology, Head and Neck Surgery,
Plastic Reconstructive Surgery, Otoneurosurgery

Indexed/Abstracted in: EMBASE, Scopus




Otorinolaringologia 2004 June;54(2):131-40

language: Italian

Antibiotic therapy in ENT-diseases

Giordano C. 1, Ponzo S. 2, Garzaro M. 1, Pecorari G. 1

1 Dipartimento di Fisiopatologia Clinica S.C. ORL I, Università degli Studi di Torino, Torino
2 Divisione di ORL Ospedale, SS. Annunziata, Savigliano (Cuneo)


Although the ­present phar­mac­o­log­ic treat­ment has ­improved the ­course and the recov­ery of ­many ENT-dis­eas­es, recent­ly an ­increase of new fea­tures and ther­a­peu­tic per­spec­tives ­occurred. The gold­en stan­dard of the ­present anti­bi­o­tic ther­a­py is the erad­i­ca­tion of the pathol­o­gy, a rap­id res­o­lu­tion of the symp­tom­a­tol­o­gy and of the infec­tive­ness, com­bined ­with a ­great reduc­tion and pre­ven­tion of ­side ­effects and com­pli­ca­tions. An anal­y­sis of the ENT-dis­eas­es dis­tri­bu­tion in Italy, ­shows in the ­first ­place the infec­tions of the mid­dle ear (55%) fol­lowed by phar­ynx-ton­sil­lar (30%) and sin­u­sal infec­tions (15%). This ­paper pro­vides ­data ­about the anti­bi­o­tic ther­a­py in phlo­gis­tic pathol­o­gies of the ear, the rhi­no-sin­u­sal dis­trict and in ­acute and chron­ic phar­ynx-ton­sil­litis, accord­ing to the ­most ­recent inter­na­tion­al guide­lines. In the clin­i­cal prac­tice, a ­first anti­bi­o­tic ther­a­py is rare­ly ­based on the iden­tifi­ca­tion of the respon­sible ­germ and on the anti­bi­o­gram. At ­least at the begin­ning, ther­a­py is ­planned on an empir­ic ­basis, there­fore the use of ­large spec­trum anti­bi­o­tics is abso­lute­ly nec­es­sary: ­this ­choice ­involves cri­te­ria of thought­ful use, in ­order to ­avoid neg­a­tive ­impacts ­both ­from a clin­i­cal ­point of ­view, due to the non-res­o­lu­tion of the prob­lem and pos­sible ­side ­effects, and ­from the eco­nom­i­cal ­point of ­view, due to the ­costs depend­ing on the bad use of the ­drugs.

top of page

Publication History

Cite this article as

Corresponding author e-mail